CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 59 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,123,947 | +25.6% | 372,146 | +82.9% | 0.01% | +42.9% |
| Q2 2023 | $6,467,644 | +46.3% | 203,449 | +12.3% | 0.01% | +40.0% |
| Q1 2023 | $4,420,029 | -24.5% | 181,223 | -2.3% | 0.01% | -28.6% |
| Q4 2022 | $5,852,058 | +13.2% | 185,544 | 0.0% | 0.01% | +16.7% |
| Q3 2022 | $5,171,000 | +6.9% | 185,544 | +1.4% | 0.01% | 0.0% |
| Q2 2022 | $4,839,000 | -29.4% | 183,008 | -6.5% | 0.01% | 0.0% |
| Q1 2022 | $6,855,000 | -2.2% | 195,808 | -9.4% | 0.01% | 0.0% |
| Q4 2021 | $7,006,000 | +36.1% | 216,108 | +23.9% | 0.01% | +20.0% |
| Q3 2021 | $5,147,000 | +35.1% | 174,476 | +12.9% | 0.01% | +25.0% |
| Q2 2021 | $3,809,000 | +141.8% | 154,590 | +34.8% | 0.00% | +100.0% |
| Q1 2021 | $1,575,000 | +155.7% | 114,715 | +208.7% | 0.00% | +100.0% |
| Q4 2020 | $616,000 | – | 37,158 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,314,160,084 | 42.08% |
| Perceptive Advisors | 10,088,385 | $220,229,445 | 7.35% |
| Finepoint Capital LP | 563,345 | $12,297,821 | 6.12% |
| Affinity Asset Advisors, LLC | 685,061 | $14,954,882 | 4.21% |
| Paradigm Biocapital Advisors LP | 2,532,972 | $55,294,779 | 3.75% |
| Logos Global Management LP | 700,000 | $15,281,000 | 2.04% |
| Artal Group S.A. | 1,638,858 | $35,776 | 1.53% |
| Rock Springs Capital Management LP | 2,529,116 | $55,210,602 | 1.48% |
| GREAT POINT PARTNERS LLC | 215,000 | $4,693,450 | 0.86% |
| Frazier Life Sciences Management, L.P. | 393,000 | $8,579,190 | 0.57% |